Abstracts tagged "osteoclastogenesis and tumor necrosis factor (TNF)"

Abstract Number: 1338 • 2017 ACR/ARHP Annual Meeting
Important Role of CD11c+ Dendtritic Cells in Inflammatory Arthritis
Antonia Puchner¹, Victoria Saferding¹, Michael Bonelli², Harald Leiss³, Gerhard Krönke⁴, René Pfeifle⁵, Josef S. Smolen⁶, Kurt Redlich⁷ and Stephan Blüml⁶, ¹Medical University of Vienna, Austria, Vienna, Austria, ²Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rheumatology, Medical University Vienna, Vienna, Austria, ⁴Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Austria, ⁵Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁶Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, ⁷Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Dendritic cells (DCs) are important antigen presenting cells (APCs) and therefore they play an important role in bridging the innate and the adaptive immune…
Abstract Number: 1948 • 2017 ACR/ARHP Annual Meeting
TNF-α Overrides the Ability of RANK Ligand to Induce Osteoclast Differentiation of Classical Circulating Precursors
Cecilia Ansalone¹, Flavia Sunzini¹, Caitlin Duncan¹, Sabarinadh Chilaka¹, Iain B. McInnes² and Carl S. Goodyear³, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²University of Glasgow, Glasgow, United Kingdom, ³Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: TNF-α is well known to be involved in inflammatory-induced bone destruction. This is widely supported by clinical studies showing reduced bone pathology after anti-TNF-α…
Abstract Number: 1826 • 2013 ACR/ARHP Annual Meeting
Immune Complex Formation By Adalimumab Contributes Significantly To Its Inhibitory Effect On TNF-Enhanced Human Osteoclast Development Even In The Absence Of Fc Receptor Binding
Bohdan P. Harvey and Zehra Kaymakcalan, Biologics, AbbVie Bioresearch Center, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …
Abstract Number: 5 • 2012 ACR/ARHP Annual Meeting
Adalimumab Inhibits TNF-Enhanced Human Osteoclast Development More Effectively Than Other Biologic Agents Under in Vitro Conditions of Chronic TNF Exposure
Bohdan P. Harvey¹ and Zehra Kaymakcalan², ¹Biologics, Abbott Laboratories, Worcester, MA, ²Biologics, Abbott, Worcester, MA
Background/Purpose: TNF-alpha (TNFa) has been shown to contribute to osteoclastogenesis independently and in conjunction with M-CSF or RANKL, two key cytokines involved in osteoclast development. …

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].